Abiomed, Inc. (NASDAQ:ABMD – Get Ranking) has acquired a mean suggestion of “Hold” from the eight rankings corporations which might be presently protecting the inventory, MarketBeat Scores reviews. Seven equities analysis analysts have rated the inventory with a maintain ranking and one has given a purchase ranking to the corporate. The common 1-year goal value amongst brokers which have issued rankings on the inventory within the final yr is $350.50.

A number of analysis analysts have commented on the inventory. William Blair lower shares of Abiomed from an “outperform” ranking to a “market carry out” ranking in a analysis report on Tuesday, November 1st. Mizuho initiated protection on Abiomed in a report on Wednesday, October twelfth. They set a “purchase” ranking and a $300.00 value goal on the inventory. Morgan Stanley upgraded Abiomed from an “underweight” ranking to an “equal weight” ranking and raised their goal value for the corporate from $235.00 to $380.00 in a analysis be aware on Wednesday, November 2nd. StockNews.com assumed protection on Abiomed in a analysis report on Wednesday, October twelfth. They issued a “maintain” ranking for the corporate. Lastly, Deutsche Financial institution Aktiengesellschaft lowered shares of Abiomed from a “purchase” ranking to a “maintain” ranking and boosted their value goal for the corporate from $355.00 to $388.00 in a report on Wednesday, November 2nd.

Insider Shopping for and Promoting

In associated information, VP Marc A. Started bought 2,000 shares of the corporate’s inventory in a transaction on Friday, November 4th. The shares have been bought at a mean value of $373.71, for a complete worth of $747,420.00. Following the completion of the transaction, the vice chairman now instantly owns 13,785 shares within the firm, valued at $5,151,592.35. The sale was disclosed in a doc filed with the Securities & Alternate Fee, which could be accessed by means of this hyperlink. In different Abiomed information, Director Paul Thomas bought 1,000 shares of the corporate’s inventory in a transaction dated Tuesday, November 1st. The shares have been bought at a mean value of $379.38, for a complete transaction of $379,380.00. Following the completion of the sale, the director now instantly owns 6,357 shares within the firm, valued at $2,411,718.66. The transaction was disclosed in a doc filed with the SEC, which is accessible by means of this hyperlink. Additionally, VP Marc A. Started bought 2,000 shares of the corporate’s inventory in a transaction dated Friday, November 4th. The shares have been bought at a mean value of $373.71, for a complete transaction of $747,420.00. Following the sale, the vice chairman now owns 13,785 shares of the corporate’s inventory, valued at $5,151,592.35. The disclosure for this sale could be discovered right here. Over the past ninety days, insiders bought 6,544 shares of firm inventory price $2,468,594. Company insiders personal 2.50% of the corporate’s inventory.

Institutional Buying and selling of Abiomed

Institutional buyers have not too long ago added to or decreased their stakes within the enterprise. Crossmark World Holdings Inc. raised its stake in shares of Abiomed by 1.9% throughout the first quarter. Crossmark World Holdings Inc. now owns 2,720 shares of the medical tools supplier’s inventory valued at $901,000 after buying a further 50 shares over the last quarter. US Bancorp DE raised its stake in Abiomed by 46.3% within the first quarter. US Bancorp DE now owns 6,433 shares of the medical tools supplier’s inventory price $2,131,000 after shopping for a further 2,035 shares within the final quarter. Pinebridge Investments L.P. purchased a brand new place in Abiomed within the first quarter price about $25,000. Cambridge Funding Analysis Advisors Inc. raised its stake in Abiomed by 7.8% within the first quarter. Cambridge Funding Analysis Advisors Inc. now owns 910 shares of the medical tools supplier’s inventory price $301,000 after shopping for a further 66 shares within the final quarter. Lastly, Blueshift Asset Administration LLC purchased a brand new place in shares of Abiomed throughout the first quarter valued at roughly $314,000. 94.48% of the inventory is presently owned by hedge funds and different institutional buyers.

Abiomed Inventory Efficiency

NASDAQ ABMD opened at $381.02 on Monday. Abiomed has a one yr low of $219.85 and a one yr excessive of $381.99. The corporate’s 50 day transferring common value is $351.42 and its 200 day transferring common value is $294.31. The agency has a market capitalization of $17.18 billion, a price-to-earnings ratio of 65.47, a PEG ratio of three.33 and a beta of 1.40.

Abiomed (NASDAQ:ABMD – Get Ranking) final posted its quarterly earnings information on Tuesday, November 1st. The medical tools supplier reported $1.30 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.05 by $0.25. The corporate had income of $265.92 million for the quarter, in comparison with analyst estimates of $273.30 million. Abiomed had a web margin of 24.84% and a return on fairness of 14.77%. Promote-side analysts forecast that Abiomed will put up 4.58 EPS for the present fiscal yr.

About Abiomed

(Get Ranking)

Abiomed, Inc engages within the analysis, growth, and sale of medical units to help or exchange the pumping operate of the failing coronary heart. It additionally supplies a continuum of care to coronary heart failure sufferers. The corporate gives Impella 2.5, a percutaneous micro coronary heart pump with built-in motor and sensors; and Impella CP, a tool to be used by interventional cardiologists to help sufferers within the cath lab, in addition to by cardiac surgeons within the coronary heart surgical procedure suite.

Featured Tales

This immediate information alert was generated by narrative science expertise and monetary information from MarketBeat with the intention to present readers with the quickest and most correct reporting. This story was reviewed by MarketBeat’s editorial staff previous to publication. Please ship any questions or feedback about this story to contact@marketbeat.com.

Earlier than you take into account Abiomed, you will wish to hear this.

MarketBeat retains observe of Wall Road’s top-rated and finest performing analysis analysts and the shares they advocate to their purchasers each day. MarketBeat has recognized the 5 shares that prime analysts are quietly whispering to their purchasers to purchase now earlier than the broader market catches on… and Abiomed wasn’t on the checklist.

Whereas Abiomed presently has a “Hold” ranking amongst analysts, top-rated analysts imagine these 5 shares are higher buys.

View The 5 Shares Right here